Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress
-- First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with…
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors
-- Veteran biopharmaceutical executive Mark Alles brings more than three decades of global hematology and oncology experience, and significant corporate…
Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023
-- Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) -- -WU-NK-101 demonstrated…
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design